THAM-E Drug Patent Profile

When do Tham-e patents expire, and what generic alternatives are available?

Tham-e is a drug marketed by Hospira and is included in one NDA.

The generic ingredient in THAM-E is potassium chloride; sodium chloride; tromethamine. One supplier is listed for this compound. Additional details are available on the potassium chloride; sodium chloride; tromethamine profile page.

Summary for THAM-E

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for THAM-E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	THAM-E	potassium chloride; sodium chloride; tromethamine	INJECTABLE;INJECTION	013025-001	Approved Prior to Jan 1, 1982		DISCN	No	No

THAM-E (Tris( hydroxymethyl )aminomethane) Injection) Investment Scenario and Fundamentals Analysis: Patent/Exclusivity, FDA Status, and Generic Risk

Last updated: June 16, 2026

THAM-E is a legacy, off-patent small-molecule infusion product; the investable return profile is driven less by patent exclusivity and more by supply continuity, regulatory maintainability, and cost-down manufacturing execution. Patent-driven upside is typically limited because “THAM-E” products are usually sold as generic-equivalent injection formulations under established regulatory/compendial pathways rather than as novel, independently protected drugs.

What is THAM-E and how does the product generate revenue?

Featured snippet: THAM-E’s commercial engine is selling a buffered infusion (THAM) for clinical indications that include metabolic acidosis management; revenue is concentrated in hospital purchasing, tender cycles, and channel availability rather than brand premium.

What does THAM-E contain and what dosage forms exist?

• Active ingredient: THAM (Tris(hydroxymethyl)aminomethane), a buffering agent.
• Common dosage form in THAM products: parenteral injection (IV).
• Typical commercial structure: packaged injectable product for inpatient use.

Who buys THAM-E and what drives volume?

• Primary buyers: hospitals, group purchasing organizations (GPOs), wholesalers.
• Key volume drivers:
  • hospital formularies and interchangeability with sodium bicarbonate and other buffers
  • procurement price under tender-based competition
  • consistent supply (shortages swing share quickly)
  • regulatory status and lot release timeliness

What is the competitive marketplace shape?

• The market is characterized by:
  • multiple suppliers of THAM injection in many jurisdictions
  • high price sensitivity due to limited differentiation
  • low marketing intensity compared with specialty, patent-protected drugs

What patents protect THAM-E, and how strong is the patent estate?

Featured snippet: THAM-E exposure is usually not protected by a long-running core drug patent; the IP layer, if present, tends to be limited to manufacturing process, specific formulation parameters, or packaging/administration details.

How to assess whether THAM-E has meaningful exclusivity

Investment relevance hinges on whether any of the following exist and are enforceable in the US:

• composition-of-matter patent on THAM as an active ingredient (rare for “THAM injection” brands)
• formulation patent covering a specific THAM concentration, pH, excipient system, or stability-relevant composition (common, but often narrow)
• manufacturing process patents (often narrow and hard to enforce against product equivalence)
• method-of-use patents (usually weak for established indications if not novel)

Likely IP reality for buffered IV agents

For widely used buffer actives like THAM, the core chemistry is mature. The practical implication for investors: unless THAM-E is tied to a specific, still-live FDA-listed reference product with robust, late-expiring patents, the upside is usually supply-based rather than IP-based.

When does THAM-E lose exclusivity and how do exclusivity and patent terms affect entry?

Featured snippet: For legacy injection products, exclusivity is often already expired; any remaining protection is typically facility- or process-specific and does not block standard generic/ANDA entry if listed references are off-patent and no blocking patents are Orange Book listed.

Patent expiration vs FDA exclusivity (how they interact)

• If there are no blocking Orange Book patents, generic manufacturers can file based on:
  • Abbreviated New Drug Application (ANDA) referencing an approved reference listed drug (RLD)
• If there are blocking patents, entry may require:
  • Paragraph IV certifications with Hatch-Waxman litigation
  • or non-infringing design-around, which is uncommon for simple buffers if equivalence specs are met

What “generic entry risks” matter most for THAM-E?

For injection buffers, the risk profile is dominated by:

• interchangeability and therapeutic equivalence acceptance in hospital formularies
• manufacturing compliance and lot release continuity
• risk of regulator actions that pause distribution

What is the Orange Book status of THAM-E?

Featured snippet: THAM-E’s value driver is whether any currently listed Orange Book patents create legal barriers to ANDA entry; for mature buffer injection products, Orange Book protections often do not materially restrict competition.

How Orange Book listings map to investment outcomes

• If THAM-E has a live RLD with multiple active patents listed:
  • generic entry is delayed until patent expiry, or contested via Paragraph IV
• If THAM-E has few or no active patents listed:
  • ANDA entry can occur without long litigation schedules
  • margin pressure increases quickly after launch

What FDA pathway does THAM-E use, and what regulatory events affect supply?

Featured snippet: Most THAM injection products are approved as small-molecule injectables; competition is driven by ANDA approvals and CMC compliance, with business risk concentrated in manufacturing and regulatory maintenance.

Approval and maintenance milestones that swing supply

• Chemistry, manufacturing, and controls (CMC) changes can trigger:
  • supplements (prior approval supplements or changes being effected)
  • inspection outcomes affecting batch release
• Inspection findings can force:
  • temporary suspension of production
  • delays in distribution and missed tender cycles

Bioequivalence considerations

• For buffered injectables, generic entry typically hinges on:
  • sameness in formulation and strength
  • appropriate bioequivalence bridging is commonly waived or handled via IV equivalence frameworks
  • analytical comparability and stability data for shelf-life support

What patent litigation affects THAM-E and generic launch timing?

Featured snippet: Unless THAM-E is tied to an RLD with live, blocking Orange Book patents, litigation tends to be limited; the timing of generic entry is more often determined by CMC readiness and ANDA approval rather than Hatch-Waxman stays.

How to model timing for generic and biosimilar equivalents

• If Paragraph IV cases exist, generic entry can be stayed via:
  • 30-month stay triggered by litigation filings
  • settlements that delay launch
• For older small-molecule injectables, the most common pattern is:
  • limited litigation
  • faster ANDA launches once approvals are granted

What formulations are protected for THAM-E, and are there defensible manufacturing/IP barriers?

Featured snippet: For buffer injections, formulation patents usually focus on concentration, pH, excipients, and stability. Manufacturing-process protections exist but are often narrow and difficult to block a functionally equivalent ANDA product if equivalence specs are met.

Common formulation-change levers

• THAM concentration
• pH specification and buffer capacity range
• excipient system for osmolality and stability
• sterilization and container-closure compatibility

CMC barriers that can be harder than patents

Even when patents are weak, barriers to entry can include:

• reliable sterile fill-finish capacity
• stability-indicating methods and shelf-life data
• container-closure compatibility qualification
• batch-to-batch control of pH and osmolarity

How does THAM-E compare with sodium bicarbonate and other buffers?

Featured snippet: Buffered-acidosis treatment competition is primarily clinical protocol driven; generic THAM and bicarbonate interchangeability reduces brand leverage and shifts market power to supply and price.

Clinical protocol factors that affect procurement

• institution-specific practice guidelines
• tolerance and monitoring requirements
• availability and procurement pricing
• clinician preference based on perceived efficacy and side-effect profile

Investment implication

If THAM competes on protocol adherence rather than patent-protected performance, then:

• price compression is the default outcome
• supply assurance becomes the central moat

Which companies are likely suppliers or challengers for THAM-E?

Featured snippet: THAM injection is typically supplied by multiple generic manufacturers; challenger activity is usually driven by ANDA filing pipelines and sterile manufacturing capacity, not by complex IP landscapes.

What to watch in competitive intelligence

• ANDA approval announcements for THAM injection
• manufacturing site expansions or closures
• GMP inspection outcomes
• distributor contract wins and hospital tender awards

What is the best investment case for THAM-E: supply, channel, or IP?

Featured snippet: The most realistic investable thesis for THAM-E is supply reliability plus manufacturing cost-down, not patent-driven exclusivity.

Supply-and-margin thesis

• Focus on:
  • capacity utilization and lead times
  • procurement contracts that stabilize demand
  • yield improvements in fill-finish
  • working-capital efficiency (inventory and batch scheduling)

Channel and contracting thesis

• Hospitals buy via tender cycles:
  • winners secure volume at lower prices
  • losers face shelf exposure and delayed reorder
• Investment-grade contracting improves downside resilience.

Patent-driven thesis (only if Orange Book supports it)

A patent-based case requires:

• still-live, blocking Orange Book patents for the specific THAM-E RLD
• credible enforcement posture and clear infringement positions Without live patents, the patent thesis is usually structurally weak.

Key commercial sensitivities for THAM-E

Featured snippet: THAM-E economics are sensitive to reimbursement and price pressure, but most acute sensitivity comes from supply interruptions and tender-based pricing.

Top downside risks

• rapid price erosion after generic entry
• sterile manufacturing disruption
• regulatory holds or batch recalls
• distributor contract loss during shortages or quality events

Top upside levers

• sustained supply with minimal lot rejection
• procurement contract wins with favorable pricing terms
• manufacturing debottlenecking and cost reductions
• rapid regulatory maintenance and change management

Key Takeaways

• THAM-E is a mature buffered IV injection product; the investable upside is usually supply and execution rather than long-running patent exclusivity.
• The critical gating variable is the Orange Book and whether any live, blocking patents are listed for the THAM-E RLD; absent that, generic entry dynamics depend on ANDA approvals and CMC readiness.
• Revenue is hospital/tender driven with high price sensitivity; sustaining reliable manufacturing and regulatory compliance is the primary risk control lever.
• Competitive advantage, when present, is typically operational: fill-finish capacity, quality stability, and low landed cost.

FAQs

1. How do I find the FDA RLD and ANDA reference for THAM injection to assess generic competition timelines?
2. What manufacturing CMC risks most often disrupt sterile injectable buffer supply and lead to tender losses?
3. Do THAM injections face interchangeability switching policies that accelerate price compression after generic launches?
4. What Orange Book “blocking patent” patterns matter most for ANDA entry timing for simple IV injectables?
5. How should investors model the impact of 30-month Hatch-Waxman stays versus CMC-driven delays for legacy injectable products?

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. (n.d.). ANDA product-specific guidance and regulatory pathways. U.S. Food and Drug Administration.
3. Hatch-Waxman. (n.d.). Legislative framework for ANDAs, exclusivity, and patent certifications. U.S. legal framework summaries.